This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

57/100

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Tau biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Insulin, insulin-like growth factors (IGF) and their receptors are highly expressed in the adult hippocampus. Thus, disturbances in the insulin-IGF signalling pathway may account for the selective vulnerability of the hippocampus to nascent Alzheimer's disease (AD) pathology. In the present study, we examined the predominant IGF-binding protein in the CSF, IGFBP2.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Quesnel, M. J., Labonté, A., Picard, C., Zetterberg, H., Blennow, K., Brinkmalm, A., et al. (2024). Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains. Brain : a journal of neurology. https://doi.org/10.1093/brain/awad398

Vancouver

Quesnel MJ, Labonté A, Picard C, Zetterberg H, Blennow K, Brinkmalm A, et al. Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains. Brain : a journal of neurology. 2024. doi:10.1093/brain/awad398. PMID: 37992295.

BibTeX

@article{quesnel2024-37992295,
  author  = {Quesnel, M. J. and Labonté, A. and Picard, C. and Zetterberg, H. and Blennow, K. and Brinkmalm, A. and Villeneuve, S. and Poirier, J. and others},
  title   = {{Insulin-like growth factor binding protein-2 in at-risk adults and autopsy-confirmed Alzheimer brains}},
  journal = {Brain : a journal of neurology},
  year    = {2024},
  doi     = {10.1093/brain/awad398},
  pmid    = {37992295},
  url     = {https://doi.org/10.1093/brain/awad398}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Thus, disturbances in the insulin-IGF signalling pathway may account for the selective vulnerability of the hippocampus to nascent Alzheimer's disease (AD) pathology.
In the present study, we examined the predominant IGF-binding protein in the CSF, IGFBP2.
CSF was collected from 109 asymptomatic members of the parental history-positive PREVENT-AD cohort.
CSF levels of IGFBP2, core AD and synaptic biomarkers were measured using proximity extension assay, ELISA and mass spectrometry.

Why it matters

This study measured the protein IGFBP2 in cerebrospinal fluid from 109 asymptomatic people with a parent who had Alzheimer's disease, alongside core Alzheimer's and synaptic biomarkers. It is a biomarker study, so it does not show that changing IGFBP2 levels treats, cures or prevents the disease.

New to this subject? Start with our plain-English guide: Blood tests & biomarkers →

Study details

Study designlongitudinal study
Evidence strengthModerate

How this study scored 57/100

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 55 of the 96 points we could judge it on, which is 57 out of 100.

Component	Points	Why
Journal tier	9 / 10	Tier 2 — leading specialty journal (Brain : a journal of neurology)
Journal's citation record	4 / 4	Brain: journal h-index 503 (OpenAlex, 2026-10-29)
Study design	7 / 12	A longitudinal study following the same people over time
Strength of evidence	3 / 5	Rated “moderate” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2024 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded	0 / 2	No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	3 / 7	Cited 23 times (OpenAlex, 2026-10-10)
Citations per year	2 / 5	5.8 citations a year over 4 year(s) since 2024
Impact for its field and year	3 / 6	Cited 3.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	1 / 6	Cited by 2 other studies in this library
Still being cited	2 / 4	Cited 22 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	Senior author's record not available — left out of this score
Institution's track record	2 / 3	University College London: institution h-index 2,029 (OpenAlex)
Multi-centre collaboration	3 / 3	OpenAlex lists 12 institution(s) in 6 countries
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 37992295)
Free to read	0 / 2	Behind a paywall — scores zero
Points	55 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 55 of the 96 points we could judge it on is 57 out of 100.
Total	57 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 18.

Later studies that cite this one

2 studies in the alzhub library list this one in their references.

Related studies in Tau biomarkers

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →